The vesicular neurotransmitter transporters: current perspectives and future prospects.
about
Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese populationVMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuseIdentification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazineRelationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreasFunctional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humansSaccharomyces cerevisiae Aqr1 is an internal-membrane transporter involved in excretion of amino acidsExpression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumorsDirected evolution reveals hidden properties of VMAT, a neurotransmitter transporterModulation of behavioral phase changes of the migratory locust by the catecholamine metabolic pathway.Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosisExpression of neurotransmitter transporters for structural and biochemical studiesForebrain ischemia triggers GABAergic system degeneration in substantia nigra at chronic stages in rats.Functionally important carboxyls in a bacterial homologue of the vesicular monoamine transporter (VMAT).Biogenic amines and polyamines: similar biochemistry for different physiological missions and biomedical applications.Expression of histidine decarboxylase and synthesis of histamine by human small cell lung carcinomaPyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis.Species-specific vesicular monoamine transporter 2 (VMAT2) expression in mammalian pancreatic beta cells: implications for optimising radioligand-based human beta cell mass (BCM) imaging in animal models.Imaging the islet graft by positron emission tomography.The GABA synapse as a target for antiepileptic drugs: a historical overview focused on GABA transporters.Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport.Chemical coding of the human gastrointestinal nervous system: cholinergic, VIPergic, and catecholaminergic phenotypes.Chromogranin A and vesicular monoamine transporter 2 immunolocalization in protein bodies of human locus coeruleus neurons.The vesicular monoamine transporter 2 (VMAT2) is expressed by normal and tumor cutaneous mast cells and Langerhans cells of the skin but is absent from Langerhans cell histiocytosis.Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.Differential regulation of catecholamine synthesis and transport in rat adrenal medulla by fluoxetine treatment.Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis.
P2860
Q21203891-535361D8-E6F6-465F-9A44-07633E140DF6Q22242306-07E9324A-208B-407B-AA95-3BBA817D3A22Q24601521-F6BD36C8-F3CE-43C5-9AE4-95A6F451A44DQ24653211-B4225B1C-CA9E-4A9B-A78A-D6A610BFDEE3Q24654140-01A1A193-C081-4A19-9FDC-83946F1AD744Q27931298-0FF906EB-0679-4270-BA68-58A33E11450AQ28188312-0E3D7722-8759-4AD3-91BC-39DF52BBA951Q28573346-E38575DC-0DD0-4E3D-BEBD-27EBDC2CB8F5Q30498501-18BA614D-3EC8-4664-A7D7-9D74A0A6B2B7Q33862898-2E2C54F5-CE4D-488E-972C-2BB9BEFE6BD8Q34032615-C306E92B-B1B2-432F-936A-1BB5357C408FQ34215178-03022947-685B-4D86-A8EC-86E29175D6ECQ34634284-9BAE72CC-AA4B-4DBC-9100-5431084B0FA9Q35086731-48D8573B-DECE-4C92-AA30-7D4E474D9F14Q35748115-D700F5F4-419F-4F85-9AA3-DF6DB686B087Q37052450-1C220726-0989-45BC-B136-2E87901747D1Q37451183-BD2C0793-253F-43A6-A2D9-ADCC757B887FQ37640085-06AEC631-19CD-402F-B243-9BBA834F9F26Q37935646-E7EBE795-C88E-4FEF-9362-99FAC337D3B4Q38195817-2FC36911-387A-497D-B35E-F782B543C15FQ43619030-02FA166B-3262-4B32-ADD4-C4A036E122AFQ44357603-FE3CC6E0-149C-48C9-BB08-FB9231179D78Q45203790-D8989A0C-F89A-4D6D-BD1A-31F9C112C5E1Q47585008-608B23BD-EEC2-4339-B486-CB87DE3490AFQ47753620-BD3CB2CE-7780-414A-AA08-8915B2059A1FQ54175314-587F1EAA-AE23-4FDC-B7E3-C3A4B431CEE5Q54647310-4597ACA6-8C6E-4480-879E-5CDB57878B5C
P2860
The vesicular neurotransmitter transporters: current perspectives and future prospects.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The vesicular neurotransmitter transporters: current perspectives and future prospects.
@ast
The vesicular neurotransmitter transporters: current perspectives and future prospects.
@en
The vesicular neurotransmitter transporters: current perspectives and future prospects.
@nl
type
label
The vesicular neurotransmitter transporters: current perspectives and future prospects.
@ast
The vesicular neurotransmitter transporters: current perspectives and future prospects.
@en
The vesicular neurotransmitter transporters: current perspectives and future prospects.
@nl
prefLabel
The vesicular neurotransmitter transporters: current perspectives and future prospects.
@ast
The vesicular neurotransmitter transporters: current perspectives and future prospects.
@en
The vesicular neurotransmitter transporters: current perspectives and future prospects.
@nl
P356
P1433
P1476
The vesicular neurotransmitter transporters: current perspectives and future prospects.
@en
P2093
P304
P356
10.1096/FJ.00-0817REV
P407
P577
2000-12-01T00:00:00Z